Drug Safety, Shortages & Recalls

Safety alerts, recalls, shortages, labeling changes, and medication warnings from trusted authorities.

Diabetes | Drug Safety, Shortages & Recalls | Medical Devices & Diagnostics | Patient Safety & Quality

FDA Class I Recall for Some FreeStyle Libre 3 Sensors: What People With Diabetes Should Do Now
March 27, 2026 12:15 pm

The FDA has classified a recall for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors as Class I, its most serious recall type. The issue is falsely low glucose readings from some sensor lots. Here is what is affected, what is not, how to check your sensor, and what to do if a reading does not match how you feel.

Read More FDA Class I Recall for Some FreeStyle Libre 3 Sensors: What People With Diabetes Should Do Now
Drug Safety & Recalls | Drug Safety, Shortages & Recalls | Healthcare Policy & Access | Prescriptions

U.S. Drug Shortages in 2026: What the FDA List Means for Patients and How to Protect Your Care
March 20, 2026 9:36 pmMarch 25, 2026 10:41 pm

Drug shortages remain a nationwide issue in early 2026. Here’s what it means when a medication appears on the FDA’s Drug Shortages list, how shortages differ from recalls, and what patients should do to protect their care.

Read More U.S. Drug Shortages in 2026: What the FDA List Means for Patients and How to Protect Your Care
Diabetes | Drug Safety & Recalls | Drug Safety, Shortages & Recalls | Obesity

FDA Warns About Risks Linked to Compounded GLP-1 Drugs: What Patients Need to Know
March 20, 2026 9:34 pmMarch 25, 2026 10:41 pm

The FDA has issued recent safety communications about compounded versions of popular GLP-1 drugs such as semaglutide and tirzepatide, warning of dosing errors, ingredient differences, and potential contamination. Here’s what patients and families should understand about the risks, legal limits, and how to protect themselves.

Read More FDA Warns About Risks Linked to Compounded GLP-1 Drugs: What Patients Need to Know
ADHD | Drug Safety, Shortages & Recalls | Mental Health | Telemedicine

ADHD Medications in 2026: What Telehealth Rules and Ongoing Stimulant Shortages Mean for Patients
March 15, 2026 4:26 pmMarch 25, 2026 10:42 pm

Federal telehealth flexibilities for prescribing ADHD stimulants were extended through December 31, 2025, while medication shortages continue into 2026. Here’s what patients and families across the United States should know about access, insurance, and practical next steps.

Read More ADHD Medications in 2026: What Telehealth Rules and Ongoing Stimulant Shortages Mean for Patients
Diabetes | Drug Safety, Shortages & Recalls | Healthcare Policy & Access

As FDA Tightens Policy on Compounded GLP-1 Drugs, What Patients Should Know About Access, Safety, and Cost
March 15, 2026 5:33 amMarch 25, 2026 10:43 pm

The FDA has updated its shortage listings and enforcement posture around compounded semaglutide and tirzepatide. Here’s what that could mean for patients who rely on these medications for diabetes or weight management.

Read More As FDA Tightens Policy on Compounded GLP-1 Drugs, What Patients Should Know About Access, Safety, and Cost
Drug Safety, Shortages & Recalls | Mental Health | Obesity

Why the FDA Is Reconsidering Suicidal-Ideation Warnings for Some GLP-1 Weight-Loss Drugs
March 15, 2026 5:31 amMarch 25, 2026 10:43 pm

Federal regulators say current evidence does not show a clear link between GLP-1 weight-loss drugs and suicidal thoughts. Here’s what the FDA reviewed, what the data show, and what patients should watch for.

Read More Why the FDA Is Reconsidering Suicidal-Ideation Warnings for Some GLP-1 Weight-Loss Drugs
Drug Safety, Shortages & Recalls | Health Costs & Coverage | Healthcare Policy & Access

What Changing FDA Policy on Compounded GLP-1 Drugs Could Mean for Access, Safety, and Cost
March 15, 2026 2:21 amMarch 25, 2026 10:43 pm

As the FDA updates its policies around compounded versions of GLP-1 drugs like semaglutide and tirzepatide, patients may see changes in availability, pricing, and oversight. Here’s what the shift means for access, safety, and insurance coverage.

Read More What Changing FDA Policy on Compounded GLP-1 Drugs Could Mean for Access, Safety, and Cost
Drug Safety, Shortages & Recalls | Maternal & Infant Health | Patient Safety & Quality

How the FDA Says It Is Changing Recall Oversight After the Infant Botulism and Infant-Formula Response
March 15, 2026 2:17 amMarch 25, 2026 10:44 pm

After criticism over how infant formula shortages and infant botulism recalls were handled, the FDA says it is strengthening recall oversight, improving communication, and moving faster when infant health is at risk. Here’s what that means for families.

Read More How the FDA Says It Is Changing Recall Oversight After the Infant Botulism and Infant-Formula Response
Drug Safety, Shortages & Recalls | Hospitals & Healthcare Systems | Patient Safety & Quality

Patient Safety at Home and in the Hospital: What Every Family Should Know in 2026
March 15, 2026 12:42 amMarch 25, 2026 10:44 pm

Medical errors, medication mix-ups, and preventable infections remain major patient-safety concerns in the United States. Here’s what federal health agencies say patients and families can do to lower risks and improve care quality.

Read More Patient Safety at Home and in the Hospital: What Every Family Should Know in 2026
Drug Safety, Shortages & Recalls | Patient Safety & Quality | Public Health

How to Check Drug Recalls and Shortages in 2026: What U.S. Patients Should Know
March 15, 2026 12:25 amMarch 25, 2026 10:45 pm

Drug recalls and medication shortages continue to affect patients nationwide. Here’s how to check if your medication is affected, what to do next, and where to find reliable updates from U.S. health agencies.

Read More How to Check Drug Recalls and Shortages in 2026: What U.S. Patients Should Know

End of content